Peer review reports
From: CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
| Original Submission |
| 8 Mar 2023 |
Submitted |
Original manuscript
|
| Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
| Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
| 27 May 2023 |
Reviewed |
Reviewer Report
|
| 6 Jun 2023 |
Reviewed |
Reviewer Report
|
| 19 Jun 2023 |
Author responded |
Author comments - Ying Fan
|
| Resubmission - Version 4 |
| 19 Jun 2023 |
Submitted |
Manuscript version 4
|
| 26 Jun 2023 |
Author responded |
Author comments - Ying Fan
|
| Resubmission - Version 5 |
| 26 Jun 2023 |
Submitted |
Manuscript version 5
|
| 3 Jul 2023 |
Author responded |
Author comments - Ying Fan
|
| Resubmission - Version 6 |
| 3 Jul 2023 |
Submitted |
Manuscript version 6
|
| 13 Jul 2023 |
Author responded |
Author comments - Ying Fan
|
| Resubmission - Version 7 |
| 13 Jul 2023 |
Submitted |
Manuscript version 7
|
| 6 Aug 2023 |
Reviewed |
Reviewer Report
|
| 9 Aug 2023 |
Reviewed |
Reviewer Report
|
| Resubmission - Version 8 |
|
Submitted |
Manuscript version 8
|
| Publishing |
| 11 Aug 2023 |
Editorially accepted |
|
| 29 Aug 2023 |
Article published |
10.1186/s12885-023-11290-7
|
Learn about peer review
